Studies in mouse models support an essential role of lung adenocarcinoma (ADC) to squamous cell carcinoma (SCC) transition (AST) in the development of drug resistance. Recent observations in the clinic further suggest that this type of histological transition may be responsible for resistance to tyrosine kinase inhibitor (TKI) therapy and chemotherapy in relapsed EGFR-mutant lung ADC patients. Here we summarize the current understanding of AST and drug resistance.

中文翻译：

---

肺腺癌的鳞状上移和耐药性。

小鼠模型研究支持了肺腺癌（ADC）到鳞状细胞癌（SCC）过渡（AST）的耐药性发展。临床上的最新观察结果进一步表明，这种类型的组织学转变可能是复发性EGFR突变型肺ADC患者对酪氨酸激酶抑制剂（TKI）治疗和化疗耐药的原因。在这里，我们总结了目前对AST和耐药性的了解。